Fabry Disease – Pipeline Review, H2 Pharmaceutical Research Report 2017

Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Fabry Disease – Pipeline Review, H2 2017”. Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called globotriaosylceramide) in blood vessel walls throughout the body.

Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305513

Symptoms include pain, diarrhea, nausea, kidney problems, tinnitus, irregular heartbeat, and leaky heart valves. Treatment includes enzyme replacement therapy (ERT).

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Fabry Disease – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Fabry Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fabry Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3, 2 and 4 respectively.

Fabry Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Fabry Disease (Genetic Disorders).
– The pipeline guide reviews pipeline therapeutics for Fabry Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Fabry Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Fabry Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Fabry Disease (Genetic Disorders)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Fabry Disease (Genetic Disorders).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Fabry Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/fabry-disease-pipeline-review-h2-2017-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fabry Disease – Overview
Fabry Disease – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Fabry Disease – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fabry Disease – Companies Involved in Therapeutics Development
Amicus Therapeutics Inc
Genzyme Corp
greenovation Biotech GmbH
Idorsia Ltd
JCR Pharmaceuticals Co Ltd
Neuraltus Pharmaceuticals Inc
Pharming Group NV
Protalix BioTherapeutics Inc
Resverlogix Corp
Sangamo Therapeutics Inc
Shire Plc
Fabry Disease – Drug Profiles
agalsidase alfa – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
agalsidase alfa – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apabetalone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVRRD-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Alpha Galactosidase A for Fabry Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibiglustat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lucerastat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
migalastat hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOSS-AGAL – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-003 – Drug Profile
Product Description
Mechanism Of Action

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1305513

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact–

90 State Street,

Albany, NY 12207,

United States

Toll Free : 800-998-4852 (US-Canada)

Email : press@marketresearchhub.com

Website : http://www.marketresearchhub.com/

Read Industry News at – https://www.industrynewsanalysis.com/

Designed by CyFocus.com
Powered by CyFocus.net
%d bloggers like this: